With a "groundwork of foundational support" for Aerosurf from top-line phase IIa data plus previous work, Discovery Laboratories Inc. is going into phase IIb development of the aerosolized KL4 surfactant for preventing respiratory distress syndrome in premature infants, CEO John Cooper said. Read More
Derma Sciences Inc. is quitting the drug development business to focus exclusively on wound care devices after a committee monitoring a phase III trial of its diabetic foot ulcer (DFU) drug, aclerastide (DSC127), recommended stopping trial enrollment based on futility. Read More
LONDON – The positive data coming out of phase I/II cell and gene therapy trials is now forcing companies to focus on the issues of scaling up manufacturing and of how products – particularly autologous ones – will get to patients. Read More
Individually speaking, it's safe to call regulatory genomics, systems biology and network visualization experts a pretty clever bunch. But how smart are they together? A series of crowdsourced research challenges, mounted by IBM Research, Sage Bionetworks and big pharma is aiming to find out. Read More
Mannkind Corp., of Valencia, Calif., said it priced a registered direct offering of common stock to selected investment funds in Israel, as well as the total number of shares to be purchased in the offering. Read More
Transgene SA, of Paris, and Sillajen Inc., of Busan, South Korea, said they signed an amended agreement for the development and commercialization of oncolytic viral therapy Pexa-Vec to streamline the conduct of clinical trials and to reflect important areas of interest for each company. Read More
Complexa Inc., of Pittsburgh, disclosed completion of an extensive phase I development program for its lead compound, CXA-10, an endogenous nitro-fatty acid modulator of Nrf2 and NF-κB, which is designed to impact the core of fibrotic and inflammatory pathways. Read More
